Gilead's new drugs boost Q1 revenue 110%, but cell therapy sales decline amid competitive pressures.

Gilead Sciences saw a 110.5% quarter-on-quarter revenue increase in Q1 from its drugs Trodelvy, Livdelzi, and Yeztugo, generating $701 million. However, its cell therapy products Yescarta and Tecartus experienced a 12.3% year-on-year sales decline. The acquisition of anito-cel is viewed skeptically due to competition from J&J/Legend's Carvykti in treating multiple myeloma. This mixed performance suggests Gilead's risk and reward profile is now balanced, reflecting both growth opportunities and challenges ahead.